

BIBLIOGRAPHY

1. Aaker, D. and Joachimstaler, E., *Brand Leadership*, New York: Free Press, 2000.
2. Aaker, David A., *Managing brand equity – Capitalising on the value of a brand name*, 1991, The Free Press, New York.
3. Adarkar, Ashwin, Krishnan, Sankar, and Viswanathan, Sanoke, India's pharma challenge, *The Mckinsey Quarterly*, No. 1, 2001, pg. 126-127.
4. Audit Commission, *A prescription for movement towards more rational prescribing in general practice*, London: Audit Commission, 1996, pg. 9-12.
5. Avery, A. J., Wetzels, R. V., and Rodgers, S., Do GPs working in practice with high or low prescribing costs have different views on prescribing cost issues? *Br J Gen Pract*, 2000; 50:100-4.
6. *Ayurvedno Itihas*, 1st edition, (1968) by Pdt. Hemraj Sharma, Translated by Shri. G. M. Shastri, pg. 11-19, 37, 48-51, 462-467.
7. Baker, D., and Klein, R., Explaining outputs of primary health care: population and practice factors, *BMJ*, 1991; 303:225-9.
8. Becker, M. H., Stolley, P., and Lasagna, L., Correlates of physicians' prescribing behaviour, *Inquiry*, 1972; 9:30-42.
9. Berndt, Ernst R., Linda T., Bui, Reiley, David H., and Urban, Glen L., The roles of marketing, product quality, and price competition in the growth and composition of the U.S. Anti-Ulcer drug industry, Working paper No. 19-94, Program on the Pharmaceutical Industry, Massachusetts Institute of Technology, 1994.

10. Bhardwaj, Presht, Indian Pharmaceutical Market: An outsourcing destination, GITAM Journal of Management, Vol. 3, No. 1, 2005, pg. 114-127.
11. Blackett, T., Brand medicine: Use and future potential of branding in pharmaceutical markets, International Journal of Medical Marketing, 2001.
12. Blackett, T., Brands and Branding, Interbrand, New York, 2004.
13. Bradley, C., Factors which influence the decision whether or not to prescribe: the dilemma facing general practitioners, Br J Gen Pract, 1992; 42:454-8.
14. Britten, N., Patient demand for prescriptions: a view from the other side, Family Practice, 2000; 11: 62-66.
15. Buchholz, A. and Wördemann, W., What makes winning brands different? The hidden method behind the world's most successful brands. John Wiley & Sons Ltd, England, 2000.
16. Calfee, John E., The role of marketing in pharmaceutical research and development, Pharmacoeconomics 2002; 20 Suppl., 3: 77-85.
17. Carrin, G., Drug prescribing: a discussion of its variability and (ir)rationality, Health Policy, 1987; 73-94.
18. Carthy, P., Harvey, I., Brawn, R., and Watkins, C., A study of factors associated with cost and variation in prescribing among GPs, Family Practice, 2000; 17: 36-41.
19. Chaganti, Subba Rao, Pharmaceutical Marketing in India, GITAM Institute of Foreign Trade, 1st edition, 2005, pg. 39-46.
20. Chandler, J. and Owen, M., Developing brands with qualitative research, London: Sage, 2002.

21. Cleland, Robin, Finskud, Lars and Raimondi, Vittorio, Nine prescriptions for brand health, *Market Leader*, Spring 2004, pg. 50-55.
22. Clifton, R., *The future of brands: Brands and Branding*, Interbrand, New York, 2004.
23. Coleman, J. S., Katz, E., and Menzel, H., *Medical innovation: A diffusion study*, Indianapolis: The Bobbs-Merril Company Inc, 2000.
24. Collier J. *The Health Conspiracy How Doctors, The Drug Industry and the Government Undermine our Health*. London: Hutchinson Ltd, 1989.
25. David, Donald A., A subtle form of retribution, *Drug and Cosmetic Industry*, 137, December 1985, pg. 21, 82.
26. de Chernatony, L. and Dall'Omo Riley, F., Experts' views about defining services brands and the principles of services branding, *Journal of Business Research*, Vol. 46, No2, 1999, pg. 182-192.
27. De Chernatony, Leslie and McDonald, Malcolm, *Creating Powerful Brands*, Oxford, Butterworth, 1994.
28. Doyle, Peter, Building Successful Brands: The Strategic Options, *Journal of Marketing Management*, 5, 1989, pg. 77-95.
29. Dr. Gala, Dhiren, *Homoeopathy for common diseases*, 1995, pg. 7-15.
30. Dr. Kumar, LakshmanY., *Brand success evaluation in selected pharmaceutical therapeutic groups*, IBRC Athens, 2005.
31. Elliott VS, New osteoporosis treatments offer diagnosis incentives: more options to prevent brittle bones and multiple fractures and imperative for treatment, *Am*

Med News 2002, April 1, http://www.ama-assn.org/sci-pubs/amnews/pick_02/hlsb0401.htm.

32. Erickson, D., Branding goes global, *The Business and Medicine Report*, 2001, pg. 60-71.
33. Forster, D. P., and Frost, C. E. B., Use of regression analysis to explain the variation in prescribing rates and costs between family practitioner committees, *Br J Gen Pract.*, 1991;41:67-71.
34. Frank Windmeijer, Eric de Laat, Rudy Douven, and Esther Mot, *Pharmaceutical Promotion and GP Prescription Behaviour*, CPB Discussion Paper, CPB Netherlands Bureau for Economic Policy, No. 30, 2004.
35. Galambos L, Sewell JE, *Networks of innovation: vaccine development at Merck, Sharp & Dohme, and Mulford, 1895-1995*, New York: Cambridge University Press, 1995.
36. Galambos L, The critical and widely misunderstood role of marketing in pharmaceutical innovation, Address delivered at Rutgers University, 6 April 2001.
37. Gatington, Huber, B. Weitz & P. Bansal, Brand introduction strategies and competition environments, *Journal of Marketing Research*, 27, 1990, pg. 390-401.
38. Gönül, Füsun F., Carter, Franklin, Petrova, Elina, and Srinivasan, Kannan, Promotion of prescription drugs and its impact on physicians' choice behaviour, *Journal of Marketing*, Vol. 65, July 2001, pg. 79-90.

39. Hansen, Flemming, Gronhaug, Kjelland, Warneryd, Karl-Erik, Excellent marketing: The concept, its measurement and implications, *Marketing and Research Today*, 18, 1990, 98-105.
40. Hardy, Len, *Successful Business strategy: how to win the market-place*, London, Kogan Page, 1987.
41. Harkness, James, *Monitoring Initiatives, Managing Service Quality*, 1992, pg. 417-419.
42. Harris, C. M., Jarman, B., and Woodman, E., *Prescribing: a suitable case for yreatment*, London: Royal College of General Practitioners, 1984.
43. Hartley, R. M., Charlton, J. R., and Harris, C. M., Patterns of physicians' use of medical resources in ambulatory settings, *Am J Public Health*, 1998; 77:565-7.
44. Healey, A., Yule, B., and Reid, J., Variations in general practice prescribing costs and implications for budget setting, *Health Econ.*, 1994; 3:47-56.
45. Howie, J. G., Clinical judgement and antibiotic use in general practice, *BMJ*, 1976; 2:1061-4.
46. IMS Global Insights, December 2006, www.imshealth.com.
47. Kapferer, J. N., *Strategic Brand Management*, London: Kogan Page, 1997.
48. Kapferer, J. N., *Strategic Brand Management*, The Free Press, New York, 1991.
49. Kleinke JD, The price of progress: prescription drugs in the health care market, *Health Affairs*, 2001; 25(5); 43-60.
50. Kotler, P., *Marketing Management*, Pearson Education, Delhi, 2005, pg. 407-414.
51. Kotler, P., *Marketing Management, The Millennium Edition*, Upper Saddle River, Prentice Hall, 2000.

52. Kshirsagar, Rajiv, The Indian Pharmaceutical Industry: Beyond 2005, Express Pharma Pulse, 2003.
53. Leffler, Keith B., Persuasion or information? The economics of prescription drug advertising, *Journal of Law and Economics*, 24 April 1981, pg. 45-74.
54. Malhotra, Naresh K., *Marketing Research: An applied orientation*, 4e, Pearson education, 2005.
55. Marks, Lawrence J. and Michael A. Kamins, The use of product sampling and advertising: effects of sequence of exposure and degree of advertising claim exaggeration on consumers' belief strength, belief confidence and attitudes, *Journal of Marketing Research*, 25 August 1988, pg. 266-281.
56. Milgrom, Paul, and Roberts, J., Limit pricing and entry under incomplete information: an equilibrium analysis, *Econometrica*, 50 March 1982, pg. 443-459.
57. Milgrom, Paul, and Roberts, J., Price and Advertising Signals of Product Quality, *Journal of Political Economy*, 94(4), 1986, pg. 796-821.
58. Minwalla, Shabnam, Drug promotion in India, *Healthy Skepticism International News*, Vol. 21, No. 9, 2003.
59. Morton, Jones T., and Pringle M., Explaining variations in prescribing costs across England, *BMJ*, 1993; 306:1731-4.
60. Moss, G. and Schuiling, I., A brand logic for pharma – a possible strategy based on FMCG experience, *International Journal of Medical Marketing*, 2001.
61. Moss, G., Pharmaceutical brands: do they really exist, *International Journal of Medical Marketing*, Vol. 2, Issue 1, 2001, pg. 23-33.

62. National Health Council statement: Direct-to-consumer prescription drug advertising: overview and recommendations, Washington DC, Jan 2002, http://www.nationalhealthcouncil.org/advocacy/DTC_paper.
63. Nelson, Paul, Advertising as information, *Journal of Political Economy*, 24 July-August 1974, pg. 729-745.
64. Nordhaus WD, The health of nations: the contribution of improved health to living standards, National Bureau of Economic Research (NBER), 2002; Working paper no. w8818, <http://www.nber.org/papers/w8818>.
65. Ono, Yumiko, Prescription-drug makers heighten hard-sell tactics, *Wall Street Journal*, August 1994.
66. Parmar, Himanshu, Opportunities for European Pharmaceutical companies in India, Frost and Sullivan Market Insight, January 2005.
67. Peltzman, S., By prescription only....or occasionally, *Regulation* 1987; 11 (3/4); 23-8.
68. Per, Lagerløv, Mitchell, Loeb, Marit, Andrew, and Per, Hjortdahl, Improving doctors' prescribing behaviour through reflection on guidelines and prescription feedback: a randomized controlled study, *Qual. Health Care* 2000; 9; 159-165.
69. Peterson, Robert A., A Meta-analysis of Cronbach's Coefficient Alpha, *Journal of Consumer Research*, Vol. 21, September 1994, pg. 381-391.
70. Pincus HA, Tanielian TL, Marcus SC, et al. Prescribing trends in psychotropic medications: primary care, psychiatry, and other medical specialties, *JAMA* 1998; 279: 526-31.

71. Pitta, Dennis, and Katsanis, Lea Prevel, Understanding brand equity for successful brand extension, *Journal of Consumer Marketing*, 12, 4, 1995, pg. 51-64.
72. Rodengen, J. L., *The legend of Pfizer*, Write Stuff Syndicate, Inc, 2000.
73. Rosenthal MB, Berndt ER, Donohue JM, et al. Promotion of prescription drugs to consumers, *N Engl. J Med* 2002; 346: 498-505.
74. Ryan, M., Yule, B., and Bond, C., Scottish general practitioners' attitudes and knowledge in respect of prescribing costs, *BMJ*, 1990; 300:1316-8.
75. Srivastava, R. K., Death Knelt to Ultra Marketing – Generic Market, *The Economic Times*, December 22, 2003.
76. Stephens, Debra Lynss, Hill, Ronal Paul and Bergman, Karyn, Enhancing the consumer product-relationship: Lessons from the QVC home shopping channel, *Journal of Business Research*, 37, 1996, pg. 193-200.
77. Stinebaugh, Craig, and Sabin, Glenn, Better sampling boosts the bottom line, *Pharmaceutical Executive*, March 2003, pg. 120-124.
78. *The Future of Branding: Learning from the challenges others have faced*, Datamonitor, May 2006.
79. Van Zandt, William, How much sampling is enough, *Pharmaceutical Executive*, Sept. 1993, pg. 92-96.
80. Van Zwanenberg, T. D., Grant, G. B., and Gregory, D. A., Can rational prescribing be assessed? *J R Coll Gen Pract*, 1987; 37:308-10.

81. Watkins, C., Harvey, I., Carthy, P., Moore, L., Robinson, E., and Brawn, R.,
Attitudes and behaviour of general practitioners and their prescribing costs: a
national cross sectional survey, *Qual. Saf. Health Care*, 2003; 12, pg. 29-34.
82. Weisz, Pam, Over-the-Counter goes under the radar, *Brandweek*, June 1996, pg.
39-42.
83. Windmeijer, Frank, de Laat, Eric, Douven, Rudy, and Mot, Esther,
Pharmaceutical Promotion and GP Prescription Behaviour, CPB Discussion
Paper, CPB Netherlands Bureau for Economic Policy Analysis, No 30, 2004.